Hims & Hers Health vs Starling Oncology
HIMS and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIMS and STLN compare
Hims & Hers Health is the larger company, worth 13 times as much as Starling Oncology ($4.6B against $357M).
Starling Oncology grew revenue faster over the last twelve months (34.6% versus 29.8% for Hims & Hers Health).
Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −5.7% compared with −6.7% at Hims & Hers Health.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIMS | STLN |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $357M |
| Share price | $19.73 | $3.50 |
| Change, 1 year | −49.4% | 2.0% |
| Change, 5 years | 170% | −54.6% |
| Beta (5Y) | 2.03 | 1.69 |
| Employees | 1,046 | 641 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.6× | 0.6× (better) |
| P/B | 13.0× | – |
| P/FCF | 560× | 18.9× (better) |
| FCF yield | 0.18% | 5.3% (better) |
| Fair value | $6.77 | – |
| Margin of safety | −191% | – |
| Growth | ||
| Revenue growth (TTM) | 29.8% | 34.6% (better) |
| Revenue growth, 5Y average | 73.6% (better) | 21.8% |
| Net income growth (TTM) | −243% | – |
| EPS growth (TTM) | −254% | – |
| Profitability | ||
| Gross margin | 63.8% | – |
| Operating margin | −8.1% | −3.4% (better) |
| Net margin | −6.7% | −5.7% (better) |
| FCF margin | 0.29% | 3.0% (better) |
| Return on equity | −40.8% | – |
| Return on invested capital | – | −96.2% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −2.0× |
| Current ratio | 0.92 | 1.11 (better) |
| Altman Z-score | 1.29 | 1.74 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 67.1% | 43.4% |
| Held by insiders | 10.9% | 56.6% |
| Insider net buying, 12 months | −$17.1M | −$11.1M (better) |
| Short interest, % of float | 24.9% | – |
Go deeper
- HIMS stock overview
- HIMS income statement
- HIMS valuation and score
- STLN stock overview
- STLN income statement
- STLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.